European Union

7 compound entries are recorded for this jurisdiction. A compound absent from this page has no verified entry here, which means the position has not been established from a primary source — not that no position exists.

  • Semaglutide

    Approved medicine · European Medicines Agency

    Authorised under three separate marketing authorisations covering two routes of administration. Indications differ by brand: the two diabetes authorisations are distinct from the weight-management authorisation, and the oral route is authorised for diabetes only.

    • Wegovy is under additional monitoring in the EU
    • The EU authorisation covers the injectable route for weight management only; a CHMP positive opinion on an extension adding tablets was adopted on 21 May 2026 with no Commission decision issued as at 30 July 2026

    Wegovy EPAR product information, Annex I · verified 2026-07-30

  • Tirzepatide

    Approved medicine · European Medicines Agency

    Authorised under a single marketing authorisation covering two distinct indications. The paediatric reach applies to the diabetes indication only; the weight-management indication is for adults.

    • Under additional monitoring in the EU
    • The paediatric reach of the diabetes indication does not extend to the weight-management indication

    Mounjaro EPAR product information, Annex I · verified 2026-07-30

  • Orforglipron

    Investigational — no marketing authorisation · European Medicines Agency

    No marketing authorisation. Under evaluation by the Committee for Medicinal Products for Human Use as procedure EMEA/H/C/006632, at the Day 120 list-of-questions stage as of the May 2026 meeting, and not among the medicines recommended for approval at the July 2026 meeting.

    Agenda, CHMP meeting 18-21 May 2026 (EMA/CHMP/93949/2026) · verified 2026-07-30

  • Retatrutide

    Investigational — no marketing authorisation · European Medicines Agency

    No marketing authorisation. Retatrutide is absent from the European Medicines Agency medicines register and from the list of medicines under evaluation, and the developer states that global submissions remain pending.

    Lilly’s triple agonist retatrutide: successful results from two additional studies · verified 2026-07-30

  • GHK-Cu

    Cosmetic ingredient · European Commission

    Listed in the Commission cosmetic ingredient database as COPPER TRIPEPTIDE-1 with the reported function skin conditioning. It appears in none of the annexes to Regulation (EC) No 1223/2009, so no prohibition, restriction, positive listing or maximum concentration applies to it, and no Scientific Committee on Consumer Safety opinion covers it.

    • Absence from the annexes is not an approval. Compliance rests on the Article 3 general safety obligation, an Article 10 safety report prepared by a qualified assessor, a responsible person established in the territory, notification to the competent authority, and Article 19 labelling using the common ingredient nomenclature
    • Copper is not prohibited as a class. Annex II lists individually named copper substances only, several restricted to hair dye products, and non-nano metallic copper is a permitted Annex IV colorant, reference 132, colour index 77400, without conditions
    • Nanoparticulate and colloidal metallic copper are prohibited in the European Union under Annex II reference 1726, added by Commission Regulation (EU) 2024/858. This bites only on nano or colloidal copper raw material, not on this complex

    CosIng ingredient record, COPPER TRIPEPTIDE-1 · verified 2026-07-31

  • AHK-Cu

    Cosmetic ingredient · European Commission

    No cosmetic ingredient database record could be found for this compound under any name searched. It appears in none of the annexes to Regulation (EC) No 1223/2009, and no Scientific Committee on Consumer Safety opinion covers it or copper peptides as a class. Its position therefore rests entirely on the general safety obligation rather than on any listing.

    • Absence from the annexes is not an approval. Compliance rests on the Article 3 general safety obligation, an Article 10 safety report prepared by a qualified assessor, a responsible person established in the territory, notification to the competent authority, and Article 19 labelling using the common ingredient nomenclature
    • Copper is not prohibited as a class. Annex II lists individually named copper substances only, several restricted to hair dye products, and non-nano metallic copper is a permitted Annex IV colorant, reference 132, colour index 77400, without conditions
    • Nanoparticulate and colloidal metallic copper are prohibited in the European Union under Annex II reference 1726, added by Commission Regulation (EU) 2024/858. This bites only on nano or colloidal copper raw material, not on this complex
    • No confirmable common ingredient name exists for this compound, which is a labelling exposure under Article 19 rather than a prohibition

    Consolidated Regulation (EC) No 1223/2009, annexes searched for this ingredient · verified 2026-07-31

  • NAD+

    Food supplement ingredient · European Commission

    Nicotinamide adenine dinucleotide is absent from the Union list of authorised novel foods, and the Novel Food Status Catalogue records it as not novel in food supplements on the basis of use before 15 May 1997, meaning its use in supplements does not require pre-market authorisation. The catalogue is expressly non-binding, and the evidential burden rests on the food business operator.

    • The not-novel status is limited to food supplements; other food uses may be novel and may require authorisation
    • The catalogue entry carries no purity, specification or source qualification
    • Precursor forms are classified differently: nicotinamide riboside chloride is an authorised novel food, and NMN is novel and unauthorised

    EU Novel Food Status Catalogue · verified 2026-07-30